The US Food and Drug Administration (FDA) has finalized a guidance that outlines the responsibilities of owners of 510(k) clearances when products are sold or transferred between companies. The final document significantly shortens certain sections, while adding new questions and answers.
BALTIMORE – Drugmakers that want to develop standalone medical devices to be used in combination with their drugs should evaluate the devices’ capabilities and requirements while engaging health authorities early, according to a panel of experts who spoke at the AFDO/RAPS Combination Products Summit on Tuesday.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has created AdvanceGxP to help companies consider good practice requirements earlier.
The US Food and Drug Administration’s (FDA) Office of Translational Sciences (OTS) and the Office of Clinical Pharmacology (OCP) recently released a new manual of procedures and policies (MAPP) which outlines the good review practices (GRPs) for the clinical pharmacology review of new drug applications (NDAs) and biologics license applications (BLAs). Both offices operate under FDA’s Center for Drug Evaluation and Research (CDER).
BALTIMORE – A panel of European regulators and industry representatives discussed how to streamline the regulatory process for combination products in the European Union at the AFDO/RAPS Combination Products Summit.
The US Food and Drug Administration (FDA) announced that, as of Monday, it will use the term “super intelligence” instead of “artificial intelligence” in all official correspondence, public communications, websites, reports, and policy documents.
BARCELONA – A panel of experts at the RAPS AI in Regulatory Conference discussed how artificial intelligence (AI) is being used by a wide range of stakeholders, including notified bodies and healthcare product manufacturers.
Brand-name and generic pharmaceutical groups are recommending clarifications to the US Food and Drug Administration’s (FDA) guidance on when to submit an abbreviated new drug application (ANDA) or a 505(b)(2) new drug application (NDA), though the groups had different stances on what changes are necessary.